10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Saturday, November 7, 2009

Solvay Pharma India Ltd:Future growth prospects and outlook,analysis/news and views

Scripscan:Solvay Pharma India Ltd

Story:Solvay Pharma India Limited engages in the manufacture and sale of pharmaceutical products in the areas of gastroenterology, women's health, neurosciences, influenza, psychiatry, hormone therapies, hepatology, perinatology, muscle relaxants, digestive enzymes, and allergy. Its products in the areas of women's health comprise Arachitol for treatment of vitamin D deficiency; B-crip for infertility and other gynecological dysfunctions associated with hyperprolactinemia; clome and nugon for female and male infertility; duphaston, which is indicated in progesterone deficiency; duvadilan that is indicated in preterm labor; Oestrogel to correct estrogen deficiency; Puregon for female infertility; and Utrogestan, which is indicated in progesterone deficiency and in menopause. The company also offers phychiatry/ENT/neurology products consisting of Ebasil for allergic rhinitis; Solspre nasal spray for postsurgical nasal care and daily nasal hygiene; Uvox for the treatment of depression and obsessive compulsive disorder; and vertin for the treatment of vertigo/dizziness and meniere's disease. Its products in the areas of gastroenterology include Colospa for the symptomatic treatment of abdominal pain and cramps, bowel disturbances, and intestinal discomfort; Creon for treatment of pancreatic exocrine or enzyme insufficiency; duphalac for the treatment of constipation and hepatic encephalopathy; eldicet for the treatment of irritable bowel syndrome; pankreoflat for the treatment of disturbed function of the pancreas, chronic inflammation of the pancreas, or absence of gastric juice; and udiliv for the treatment of liver diseases. In addition, Solvay Pharma offers Influvac, a vaccine for the prevention of influenza; collosol iodine for iodine deficiency disorders; and duodil for musculoskeletal conditions. The company is based in Mumbai, India. SPIL's strong balance sheet makes it a clear long-term investment candidate. Debt-free status & healthy cash flows year-on-year add to the defensive nature of the stock.We believe that these healthy cash flows should help the company in case a reasonable acquisition opportunity presents itself. At CMP of Rs 1000, the scrip trades at 10x CY2011E earnings.A good bet to own for a perspective of 3-5 years horizon.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner